The FDA gave fast-track status to the review of Allon Therapeutics' davunetide. The drug will undergo Phase II trials for the treatment of progressive supranuclear palsy, a fatal neurodegenerative disease.
Published in Brief:
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan